The future of precision medicine
By pairing companion imaging agents with small molecule drug conjugates (SMDCs), Endocyte can provide a more accurate picture of a patient’s disease status—and treatment prognosis. Learn more
Endocyte strives for precision in medicine
Our treatment philosophy is based on precision—targeting the right patient, the right disease, and the right cells. Learn more
Our SMDCs are designed to precisely deliver potent compounds with selective activation. Each corresponding companion imaging agent can be viewed with nuclear imaging equipment to assist in therapy selection.
Watch our technology at work
Several of our SMDCs and companion imaging agents are currently in clinical trials for treatment of:
- Prostate cancer
- Advanced solid tumors
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.
Potential treatments for advanced solid tumors of prostate and lung cancers are in Ph1 clinical trials.
Discovery Stage Agents
Endocyte currently has in early stage preclinical development a Pro-PBD TAM killer, a therapeutic for inflammatory diseases, and a therapeutic for the treatment of polycystic kidney disease.*